Rozanolixizumab clinical trials
Also written UCB7665.
How each study uses rozanolixizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the rozanolixizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Jun 2023 · RYSTIGGO · BLA 761286 (FDA, Drugs@FDA)
- European Union
- 5 Jan 2024 · Rystiggo · EMEA/H/C/005824 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 0
UCB Biopharma SRL (19) · UCB Biopharma S.P.R.L. (3) · UCB Celltech (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test rozanolixizumab, phase 3 first.
- May 2027A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Phase 3 · UCB Biopharma SRL
- Oct 2027An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisPhase 3 · UCB Biopharma SRL
- Oct 2027Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisPhase 4 · UCB Biopharma SRL
Studies
Open first, then newest update. How each study uses rozanolixizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingPhase 3UCB Biopharma SRLNCT07465289Written as Rozanolixizumab
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia GravisRecruitingPhase 3UCB Biopharma SRLNCT07463521Written as Rozanolixizumab
- An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisActive, not recruitingPhase 3UCB Biopharma SRLNCT06540144Written as rozanolixizumab
- Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia GravisActive, not recruitingPhase 4UCB Biopharma SRLNCT07246564Written as Rozanolixizumab
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Active, not recruitingPhase 3UCB Biopharma SRLNCT05063162Written as Rozanolixizumab
- A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisCompletedPhase 2/3UCB Biopharma SRLNCT06149559Written as rozanolixizumab
- A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT04124965Written as Rozanolixizumab
- A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT03971422Written as Rozanolixizumab
- A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia GravisCompletedPhase 3UCB Biopharma SRLNCT04650854Written as Rozanolixizumab
- A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating WomenCompletedPhase 1UCB Biopharma SRLNCT06720714Written as Rozanolixizumab
- A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)CompletedPhase 3UCB Biopharma SRLNCT05681715Written as Rozanolixizumab
- A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia SyndromeCompletedPhase 2UCB Biopharma SRLNCT05643794Written as rozanolixizumab
- A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisTerminatedPhase 2UCB Biopharma SRLNCT04875975Written as Rozanolixizumab
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedPhase 3UCB Biopharma SRLNCT04200456Written as Rozanolixizumab
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy ParticipantsCompletedPhase 1UCB Biopharma SRLNCT04828343Written as rozanolixizumab
- A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedPhase 3UCB Biopharma SRLNCT04596995Written as Rozanolixizumab
- Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune ThrombocytopeniaCompletedPhase 2UCB Biopharma SRLNCT02718716Written as UCB7665
- A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedPhase 3UCB Biopharma SRLNCT04224688Written as Rozanolixizumab
- A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedPhase 2UCB Biopharma S.P.R.L.NCT03861481Written as Rozanolixizumab
- A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating PolyradiculoneuropathyCompletedPhase 2UCB Biopharma SRLNCT04051944Written as Rozanolixizumab
Codes
What other systems call rozanolixizumab · ClinicalTrials.gg INT000963
- MeSH (NLM) C000627812rozanolixizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) P7186074QCROZANOLIXIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q120491843rozanolixizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152270RozanolixizumabOne source FDA
- DrugBank DB14919One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000627812 | rozanolixizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | P7186074QC | ROZANOLIXIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q120491843 | rozanolixizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152270 | Rozanolixizumab | One source FDA |
| DrugBank | DB14919 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.